Back to top
more

BioLife Solutions (BLFS)

(Delayed Data from NSDQ)

$17.19 USD

17.19
522,805

+0.17 (1.00%)

Updated Apr 24, 2024 04:00 PM ET

After-Market: $17.15 -0.04 (-0.23%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (152 out of 252)

Industry: Medical - Products

Better trading starts here.

Zacks News

Boston Scientific (BSX) Q1 Earnings and Revenues Top Estimates

Boston Scientific (BSX) delivered earnings and revenue surprises of 9.80% and 4.85%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

New Strong Sell Stocks for October 9th

BLFS, BWMN and FTEK have been added to the Zacks Rank #5 (Strong Sell) List on October 9, 2023.

New Strong Sell Stocks for September 13th

BLFS, ALCO and AFCG have been added to the Zacks Rank #5 (Strong Sell) List on September 13, 2023.

BioLife Solutions, Inc. (BLFS) Reports Q2 Loss, Misses Revenue Estimates

BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of -27.78% and 10.07%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Stryker (SYK) Q2 Earnings and Revenues Beat Estimates

Stryker (SYK) delivered earnings and revenue surprises of 6.72% and 3.42%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

BioLife Solutions, Inc. (BLFS) Reports Q1 Loss, Misses Revenue Estimates

BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of -60% and 12.89%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Lantheus Holdings (LNTH) Q1 Earnings and Revenues Surpass Estimates

Lantheus Holdings (LNTH) delivered earnings and revenue surprises of 13.95% and 7.17%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Humana (HUM) Rises 9.7% in a Year: More Room for Growth?

Humana's (HUM) individual Medicare Advantage membership growth is likely to boost premium income.

Encompass Health's (EHC) 155th Hospital Opens in Wisconsin

The Rehabilitation Hospital of Western Wisconsin is Encompass Health's (EHC) first location in the state.

Is BioLife Solutions (BLFS) Stock Outpacing Its Medical Peers This Year?

Here is how BioLife Solutions, Inc. (BLFS) and CRISPR Therapeutics AG (CRSP) have performed compared to their sector so far this year.

UnitedHealth (UNH) Plan in Indiana to Offer Pathways Program

UnitedHealth (UNH) expects the new Pathways for Aging program to serve around 100,000 people.

Brookdale Senior (BKD) February Weighted Average Occupancy Up

Brookdale Senior Living (BKD) witnesses 16 straight months of year-over-year increases in weighted average occupancy level.

Community Health (CYH) to Divest Two NC Hospitals for $320M

Community Health (CYH) expects the North Carolina hospitals' divestment to close at a later part of this year.

Humana (HUM), CD&R Backed Gentiva to Buy Assets From ProMedica

The acquisition is expected to boost Humana (HUM) and CD&R backed Gentiva's reach to over 500 locations.

Acadia Healthcare (ACHC) Q4 Earnings Miss on Rising Costs

Acadia Healthcare's (ACHC) 2023 capital expenditure for expansion initiatives is predicted to stay between $350 million and $400 million.

Is Annovis Bio (ANVS) Stock Outpacing Its Medical Peers This Year?

Here is how Annovis Bio, Inc. (ANVS) and BioLife Solutions, Inc. (BLFS) have performed compared to their sector so far this year.

BioLife Solutions, Inc. (BLFS) Reports Q3 Loss, Lags Revenue Estimates

BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of -27.78% and 2.13%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

BioLife Solutions, Inc. (BLFS) Reports Q2 Loss, Tops Revenue Estimates

BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of -755% and 3.64%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

SurModics (SRDX) Reports Q3 Loss, Misses Revenue Estimates

SurModics (SRDX) delivered earnings and revenue surprises of 12.82% and 2.46%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

BioLife Solutions, Inc. (BLFS) Reports Q1 Loss, Lags Revenue Estimates

BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of 29.17% and 4.36%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Cerus (CERS) Reports Q1 Loss, Tops Revenue Estimates

Cerus (CERS) delivered earnings and revenue surprises of 30% and 2.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

NuVasive (NUVA) Tops Q1 Earnings and Revenue Estimates

NuVasive (NUVA) delivered earnings and revenue surprises of 42.11% and 4.84%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

New Strong Sell Stocks for May 2nd

ALEC, AMRS, and BLFS have been added to the Zacks Rank #5 (Strong Sell) List on May 2, 2022

New Strong Sell Stocks for March 31st

BLFS, CRNT, and AMBA have been added to the Zacks Rank #5 (Strong Sell) List on March 31, 2022.

BioLife Solutions, Inc. (BLFS) Reports Q4 Loss, Tops Revenue Estimates

BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of -131.25% and 0.06%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?